期刊文献+

埃克替尼在晚期非小细胞肺癌靶向治疗中的效果分析 预览

Analysis on curative effects of icotinib in targeted treatment of advanced non-small cell lung cancer
在线阅读 下载PDF
收藏 分享 导出
摘要 目的探讨埃克替尼在晚期非小细胞肺癌靶向治疗中的效果分析。方法将2017年1月~2018年1月在我院肿瘤科治疗的86例晚期非小细胞肺癌患者随机分为两组,对照组采用化疗治疗,在此基础上观察组使用埃克替尼治疗,比较两组患者的近期疗效,症状缓解时间、疾病进展时间、平均生存时间,不良反应发生率,疗效与临床特征的相关性。结果观察组客观缓解率为48.84%、疾病控制率为86.05%,明显高于对照组的27.91%、69.77%(P<0.05);观察组症状缓解时间明显短于对照组,而疾病进展时间、平均生存时间明显长于对照组(P<0.05);观察组皮疹、腹泻、胃肠道不适、转氨酶轻度升高等不良反应发生率与对照组相比无明显差异(P>0.05),但观察组放射性肺炎发生率明显低于对照组(P<0.05)。结论埃克替尼在晚期非小细胞肺癌靶向治疗中的效果显著,能有效提升晚期疗效,且不良反应发生率可控,患者耐受性好,为临床治疗晚期非小细胞肺癌提供了新的选择。 Objective To explore the analysis on curative effects of icotinib in targeted treatment of advanced non-small cell lung cancer. Methods 86 patients with advanced non-small cell lung cancer who were treated in department of oncology in our hospital from January 2017 to January 2018 were randomly divided into two groups. The control group was treated with chemotherapy while the observation group was treated with icotinib on basis of the control group.The short-term curative effects,symptom relief time,time of disease progression,mean survival time,incidence of adverse reactions and correlation between curative effects and clinical features were compared between the two groups. Results The objective relief rate and disease control rate of the observation group were respectively 48.84% and 86.05%,which were significantly higher than those of the control group (27.91% and 69.77%,P < 0.05).The symptoms relief time in the observation group was significantly shorter than that in the control group,while the time of disease progression and mean survival time were significantly longer than those in the control group (P < 0.05).The incidence of adverse reactions such as rash,diarrhea,gastrointestinal discomfort and slightly increase of transaminase in the observation group was not significantly different from that in the control group (P > 0.05).However,the incidence of radioactive pneumonia in the observation group was significantly lower than that in the control group (P < 0.05). Conclusion Icotinib in targeted treatment of advanced non-small cell lung cancer has significant curative effects and it can effectively improve the late curative effects.The incidence of adverse reactions can be controlled and patients are well tolerated.It provides a new selection for clinical treatment of advanced nonsmall cell lung cancer.
作者 赵莹莹 赵如森 崔玉忠 王永涛 辛超 ZHAO Yingying;ZHAO Rusen;CUI Yuzhong;WANG Yongtao;XIN Chao(Department of Oncology,Linzi District People's Hospital,Shandong,Zibo 255400,China)
出处 《中国医药科学》 2019年第18期221-223,共3页 China Medicine And Pharmacy
关键词 晚期非小细胞肺癌 埃克替尼 靶向治疗 近期疗效 毒副反应 Advanced non-small cell lung cancer Icotinib Targeted treatment Short-term curative effects Toxic side effects
  • 相关文献

参考文献17

二级参考文献172

  • 1Liu D, Jiang J, Hu P, et al. Quantitative determination of icotinib in human plasma and urine using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sei, 2009, 877:3781-3786. 被引量:1
  • 2Ren GJ, Zhao YY, Zhu YJ, et al. Tumor gene mutations and messenger RNA expression: correlation with clinical response to icotinib hydrochloride in non-small cell lung cancer. Chin Med J (Engl), 2011, 124:19-25. 被引量:1
  • 3Zhao Q, Shentu J, Xu N, et al. Phase I study of ieofinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors. Lung Cancer, 2011, 73 : 195-202. 被引量:1
  • 4Sun Y, Shi Y, Zhang L, et al. A randomized, double blind phase Ⅲ study of icotinib versus gefitinib in patients with advanced non- small cell lung cancer (NSCLC) previously treated with chemotherapy (ICOGEN). J Clin Oncol, 2011, 29 (Suppl) : abstr 7522. 被引量:1
  • 5Mok TS, Wu YL, Thongprasert S, et al. Gefitinib or carboplatin- paclitaxel in pulmonary adenocarcinoma. N Engl J Med, 2009, 361:947-957. 被引量:1
  • 6Mitsudomi T, Morita S, Yatabe Y, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor ( WJTOG3405 ) : an open label, randomized phase 3 triM. Lancet Oncol, 2010, 11:121-128. 被引量:1
  • 7Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med, 2010, 362:2380-2388. 被引量:1
  • 8Rosell R, Moran T, Queralt C, et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med, 2009, 361:958-967. 被引量:1
  • 9Stebbing J, Harrison M, Glynne-Jones R, et al. A phase Ⅱ study to determine the ability of gefitinib to reverse fluoropyrimidine resistance in metastatic colorectal cancer (the INFORM study). Br J Cancer, 2008, 98:716-719. 被引量:1
  • 10Cappuzzo F, Ciuleanu T, Stelmakh L, et al. Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomized, placebo-controlled phase 3 study. Lancet Oncol, 2010, 11:521-529. 被引量:1

共引文献116

投稿分析

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈